Does intracoronary bolus application of abciximab reduce Major Adverse Cardiac Events (MACE) in patients with acute myocardial infarction or unstable angina undergoing emergency coronary angioplasty?
Intracoronary administration of abciximab may reduce MACE compared to intravenous administration in patients undergoing emergency angioplasty for acute coronary syndromes.
In patients with acute myocardial infarction or unstable angina undergoing emergency coronary angioplasty, intracoronary bolus application of abciximab is associated with a reduction of MACE compared with the standard intravenous bolus application of abciximab. Prospective, randomized trials are warranted to further assess intracoronary application of abciximab.
Wöhrle et al. (2003) studied this question.